One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Промомед logo
Промомед PRMD
report update icon

Quarterly report 2026-Q2
added 09-19-2026

Промомед Cash Flow 2025-2021 | PRMD

Annual Cash Flow Промомед

2025 2024 2023 2022 2021

Net Income

7.04 B 2.86 B 2.97 B 3.97 B 3.38 B

Depreciation And Amortization of Intangible Assets

1.4 B 1.1 B 1 B 600 M 400 M

Cash At End Of Period

4.21 B 4.08 B 620 M 2.14 B 260 M

Operating Cash Flow

267 M 93 M -1.19 B 2.96 B 2.04 B

Capital Expenditure

4.56 B 4.06 B 4.43 B 6.64 B 3.24 B

Free Cash Flow

-4.29 B -3.97 B -5.62 B -3.68 B -1.2 B

All numbers in RUB currency

Quarterly Cash Flow Промомед

2026-Q2 2025-Q4 2025-Q2

Net Income

2.5 B 5.64 B 1.4 B

Depreciation And Amortization of Intangible Assets

800 M 700 M 700 M

Dividends Paid

- - -

Operating Cash Flow

-1.8 B 1.01 B -743 M

Capital Expenditure

2.71 B 3.16 B 1.39 B

Free Cash Flow

-4.51 B -2.15 B -2.13 B

All numbers in RUB currency

Cash Flow Statement is one of the three key financial reports of the company Промомед, reflecting the actual cash inflows and outflows over a certain period. Unlike the income statement, which shows revenues and expenses on an accrual basis, the cash flow statement focuses on real cash flows — how much cash actually came into the company and how much was spent.

Main Sections of the Cash Flow Statement
  • Operating Activities
    This section reflects cash flows related to the company’s core operations: receipts from sales of goods and services, payments to suppliers, employee salaries, taxes, and other operating expenses. Positive cash flow from operating activities indicates the viability of the business and its ability to generate cash.
  • Investing Activities
    Shows cash movements related to the purchase and sale of long-term assets such as real estate, equipment, and investments in other companies. Negative cash flow here often indicates investments in growth, which can be a positive sign.
  • Financing Activities
    Reflects the inflow and outflow of cash related to raising and repaying capital: issuing shares, loans, dividend payments, and loan repayments. This section shows how the company finances its activities and distributes profits.

The cash flow statement is important for investors because it allows them to assess the company’s real liquidity, showing whether it has enough cash to cover current obligations and investments — this is critical for financial stability. Additionally, it helps analyze the quality of earnings, since profits reported in the income statement can be "paper" profits and may not reflect actual cash inflows; the cash flow statement reveals this difference. The presence of free cash is also crucial for evaluating the company’s ability to finance growth and pay dividends, which is important for investors. Attention should also be paid to prolonged negative cash flows from operating activities, as this may serve as a warning sign of potential problems with the core business.

Cash flow statements of other stocks in the Biotechnology sector

Issuer Price % 24h Market Cap Country
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 50.7 -1.48 % $ 6.09 M usaUSA
DBV Technologies S.A. DBV Technologies S.A.
DBVT
$ 9.03 -4.14 % $ 1.26 B franceFrance
Precision BioSciences Precision BioSciences
DTIL
$ 7.37 6.66 % $ 94.5 M usaUSA
Exelixis Exelixis
EXEL
$ 64.59 -1.88 % $ 17.5 B usaUSA
Fennec Pharmaceuticals Fennec Pharmaceuticals
FENC
$ 13.09 -2.68 % $ 374 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 0.85 -4.67 % $ 56.8 M usaUSA
BioNTech SE BioNTech SE
BNTX
$ 80.87 -0.63 % $ 19.5 B germanyGermany
Alkermes plc Alkermes plc
ALKS
$ 44.89 -2.79 % $ 7.39 B irlandaIrlanda
ANI Pharmaceuticals ANI Pharmaceuticals
ANIP
$ 68.6 -0.77 % $ 1.38 B usaUSA
AIM ImmunoTech AIM ImmunoTech
AIM
$ 0.11 -7.75 % $ 178 K usaUSA
AC Immune SA AC Immune SA
ACIU
$ 1.98 -7.28 % $ 199 M schweizSchweiz
Atara Biotherapeutics Atara Biotherapeutics
ATRA
$ 6.51 2.6 % $ 81.7 M usaUSA
Allogene Therapeutics Allogene Therapeutics
ALLO
$ 0.63 -5.62 % $ 139 M usaUSA
Altimmune Altimmune
ALT
$ 1.33 -6.03 % $ 117 M usaUSA
AnaptysBio AnaptysBio
ANAB
$ 46.65 -1.58 % $ 1.35 B usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 252.39 -1.39 % $ 15.3 B danmarkDanmark
Arcturus Therapeutics Holdings Arcturus Therapeutics Holdings
ARCT
$ 7.42 -2.37 % $ 203 M israelIsrael
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 14.7 -1.28 % $ 1.98 B canadaCanada
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 0.91 -6.96 % $ 242 M britainBritain
Atea Pharmaceuticals Atea Pharmaceuticals
AVIR
$ 3.97 0.89 % $ 324 M usaUSA
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 129.32 -4.69 % $ 6.43 B usaUSA
BridgeBio Pharma BridgeBio Pharma
BBIO
$ 75.96 -2.84 % $ 14.5 B usaUSA
BioCryst Pharmaceuticals BioCryst Pharmaceuticals
BCRX
$ 7.23 -1.3 % $ 1.52 B usaUSA
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 2.89 -5.25 % $ 200 M britainBritain
Benitec Biopharma Benitec Biopharma
BNTC
$ 7.95 -2.4 % $ 370 M usaUSA
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 8.24 2.74 % $ 387 M usaUSA
Insmed Incorporated Insmed Incorporated
INSM
$ 141.06 -2.35 % $ 28.1 B usaUSA
Iovance Biotherapeutics Iovance Biotherapeutics
IOVA
$ 6.9 -5.61 % $ 2.47 M usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.64 17.17 % $ 56.6 M israelIsrael
InMed Pharmaceuticals InMed Pharmaceuticals
INM
$ 15.56 13.57 % $ 64.8 M canadaCanada
Biohaven Pharmaceutical Holding Company Ltd. Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$ 12.36 -9.55 % $ 799 M usaUSA
Immutep Limited Immutep Limited
IMMP
$ 3.11 -9.06 % $ 4.53 B australiaAustralia
Jazz Pharmaceuticals plc Jazz Pharmaceuticals plc
JAZZ
$ 228.26 -3.46 % $ 13.9 B irlandaIrlanda
BeyondSpring BeyondSpring
BYSI
$ 0.33 -24.42 % $ 13.6 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 0.94 -7.24 % $ 94.5 M usaUSA
Johnson & Johnson Johnson & Johnson
JNJ
$ 270.2 1.18 % $ 650 B usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 4.2 -6.67 % $ 398 M usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 2.49 1.84 % $ 206 M usaUSA
Codexis Codexis
CDXS
$ 1.0 -5.17 % $ 87.1 M usaUSA
Kamada Ltd. Kamada Ltd.
KMDA
$ 7.75 -1.02 % $ 447 M israelIsrael
Compugen Ltd. Compugen Ltd.
CGEN
$ 1.83 -2.66 % $ 171 M israelIsrael
Coherus BioSciences Coherus BioSciences
CHRS
$ 0.37 -4.06 % $ 43.3 M usaUSA
Armata Pharmaceuticals Armata Pharmaceuticals
ARMP
$ 3.06 2.68 % $ 111 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 27.36 -2.15 % $ 1.82 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 0.9 -9.7 % $ 90.3 M franceFrance
Lineage Cell Therapeutics Lineage Cell Therapeutics
LCTX
$ 0.78 -4.87 % $ 179 M usaUSA
Edesa Biotech Edesa Biotech
EDSA
$ 2.01 -7.59 % $ 11.4 M usaUSA
Eli Lilly and Company Eli Lilly and Company
LLY
$ 1 345.4 -0.44 % $ 1.21 T usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 24.73 -1.9 % $ 783 M usaUSA